M&A Deal Summary

Gamma Biosciences Acquires Nirrin Technologies

On September 23, 2021, Gamma Biosciences acquired test/measurement equipment company Nirrin Technologies

Acquisition Highlights
  • This is Gamma Biosciences’ 1st transaction in the Test/Measurement Equipment sector.
  • This is Gamma Biosciences’ 3rd transaction in the United States.
  • This is Gamma Biosciences’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-09-23
Target Nirrin Technologies
Sector Test/Measurement Equipment
Buyer(s) Gamma Biosciences
Deal Type Add-on Acquisition

Target

Nirrin Technologies

Billerica, Massachusetts, United States
Nirrin Technologies is a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications for the biopharma and life science industries. Nirrin Technologies is based in Billerica, Massachusetts.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Gamma Biosciences

Menlo Park, California, United States
Category Company
Founded 2020
Sector Life Science
DESCRIPTION

Gamma Biosciences is a life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. Gamma Biosciences was founded in 2020 and is based in Menlo Park, California.

DEAL STATS #
Overall 3 of 3
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 3 of 3
Year (2021) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-18 Mirus Bio

Madison, Wisconsin, United States

Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-22 Mirus Bio

Madison, Wisconsin, United States

Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin.

Sell $600M
Mergr

Product

Company

Legal